samedi 12 mars 2016

Understanding Reimbursement for Health and Life Sciences Startups - Harvard i-lab 2015


 
Being able to answer, "Will my device get reimbursed ?" has become critical, even for early development stage life sciences companies. From early investment rounds, investors want assurance of a return on their investment, and while they may not expect start-up companies to have all the reimbursement answers, they do expect companies to have identified the correct reimbursement questions. Investors understand that potential provider customers- hospitals and physicians- want to know they can access technologies to advance health care for patients, bill and be paid for their services and preserve their bottom line. Patients play a critical role in decision-making as they weigh their out-of-pocket costs; they want to know if their insurance will cover and pay for treatments.

This presentation led by Jo Ellen Slurzberg (VP Global Health Policy, JR Associates) will focus on why it is important to create an implementable business strategy that highlights and incorporates obtaining reimbursement and/or defining the value proposition for a product so it can be successfully commercialized in the ever-changing healthcare environment.

Aucun commentaire:

Enregistrer un commentaire

Remarque : Seul un membre de ce blog est autorisé à enregistrer un commentaire.